JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2006; 47:1507-1517, doi:10.1016/j.jacc.2005.09.077 (Published online 23 March 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2005.09.077v1
47/8/1507    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cesario, D. A.
Right arrow Articles by Dec, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cesario, D. A.
Right arrow Articles by Dec, G. W.

STATE-OF-THE-ART PAPER

Implantable Cardioverter- Defibrillator Therapy in Clinical Practice

David A. Cesario, MD, PhD* and G. William Dec, MD{dagger},*

* University of California-Irvine, Irvine, California
{dagger} Cardiology Division, Massachusetts General Hospital, Heart Failure and Transplantation Unit, Boston, Massachusetts.

Manuscript received August 26, 2005; accepted September 29, 2005.

* Reprint requests and correspondence: Dr. G. William Dec, Cardiology Division, Massachusetts General Hospital, Heart Failure and Transplantation Unit, Bigelow 800, Mailstop 817, 55 Fruit Street, Boston, Massachusetts 02114. (Email: gdec{at}partners.org).

Pharmacologic treatment of heart failure has led to dramatic improvements in survival and quality of life. Nonetheless, heart failure often progresses despite treatment with diuretics, angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, aldosterone antagonists, and digoxin. Further, despite a steady decline in the risk of death from pump failure, many patients remain at high risk for sudden cardiac death. The annual incidence of sudden cardiac death in the U.S. alone has been estimated at 184,000 to over 400,000 cases. During the past decade, substantial advances have been made in the use of device-based therapy for this population. The role of the implantable cardioverter-defibrillator (ICD) continues to evolve in routine heart failure management. The current status of ICD therapy in the treatment of heart failure patients based on randomized clinical trial results and published practice guidelines is summarized in this review.

Abbreviations and Acronyms
  ARVD = arrhythmogenic right ventricular dysplasia
  ECG = electrocardiogram
  EP = electrophysiological
  HCM = hypertrophic cardiomyopathy
  ICD = implantable cardioverter-defibrillator
  LQTS = long QT syndrome
  NYHA = New York Heart Association
  SCD = sudden cardiac death




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Tosaki and I. Edes
The role of peroxiredoxins in ischemia-reperfusion-induced cardiac damage
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2586 - H2587.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.